Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus first-line chemotherapy versus first-line chemotherapy alone as neoadjuvant treatment for stage IIIA non-small cell lung cancer
ChiCTR1900026631Phase 4Recruiting
- Sponsor
- Yibin Second People's Hospital
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Yibin Second People's Hospital. Primary endpoint: Progression-free survival. Started Apr 2019; status: recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900026631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026631.